Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts, ...

A Columbia study addresses a key challenge in the diagnosis of rare genetic disorders.

Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Results enable clinical genetic testing labs to appropriately reclassify VUSs ...

A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person in Europe to receive a ...

Mary Catchpole, 19, has the same life-threatening genetic condition, activated PI3-Kinase delta syndrome (APDS) ...

A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person ... The list price for leniolisib is £352,000 per person per year but the company Pharming has agreed ...

Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...